FDA expands approval for Pfizer's cancer drug

The Food and Drug Administration on Thursday expanded the approval for Pfizer's cancer drug Sutent, reports Reuters.

The agency first approved Sutent in 2006 to treat patients with gastrointestinal stromal tumors and advanced kidney cancer. The drug has also been approved to treat a certain form of pancreatic cancer.

Under the latest approval, Sutent may now be used to treat patients who've had a kidney surgically removed to lower the risk of cancer recurrence. Sutent is the first drug approved for this indication.

More articles on supply chain:

Geisinger, Intermountain among 11 healthcare groups urging CMS to add device identifiers to claims form
Genentech earns FDA approval for hemophilia drug
6 must-reads for supply chain leaders this week

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars